Literature DB >> 1334466

Effectiveness of the antihypertensive action of lisinopril on left ventricular mass and diastolic filling.

M G Modena1, A V Mattioli, V M Parato, G Mattioli.   

Abstract

The effect of antihypertensive treatment with lisinopril (10 to 20 mg) on left ventricular mass and diastolic function was studied in 35 patients with mild to moderate hypertension. At baseline 6 and 12 months after treatment responders to lisinopril were examined by complete echo Doppler in order to measure left ventricular mass, diastolic and systolic function. Only 30 patients concluded the study follow-up. Lisinopril successfully reduced mean blood pressure (from 122 +/- 10 to 110 +/- 11 mmHg), without modification in heart rate, and left ventricular mass index (from 145 +/- 57 to 116 +/- 42 g.m-2) at month 6, with mild additional reduction at month 12. Isovolumic relaxation time was reduced but still abnormal at months 6 and 12, whereas deceleration time significantly changed only (from 230 +/- 40 to 195 +/- 35 msec) at month 12. Our results indicate that lisinopril is more successful in reducing left ventricular mass than in improving diastolic filling.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334466     DOI: 10.1093/oxfordjournals.eurheartj.a060098

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

Review 1.  Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality.

Authors:  E Kaplinsky
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

Review 2.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 3.  Left ventricular hypertrophy. Prevalence in older patients and management.

Authors:  E Paciaroni; A Fraticelli
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

4.  Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy.

Authors:  M G Modena; G Masciocco; R Rossi; P Baraldi; G Mattioli
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

5.  Are maximum P wave duration and P wave dispersion a marker of target organ damage in the hypertensive population?

Authors:  Necati Dagli; Ilgin Karaca; Mustafa Yavuzkir; Mehmet Balin; Nadi Arslan
Journal:  Clin Res Cardiol       Date:  2007-10-19       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.